NIPT

A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.

Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.

In almost 1,000 twin pregnancies with known outcomes, cell-free DNA screening of maternal blood correctly classified trisomy 21 cases 94 percent of the time.

The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.

Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.

While total revenues were up less than 1 percent, the Diagnostics division grew revenues 5 percent. Discovery & Analytical Solutions dipped 2 percent.

To help fund the acquisition, Yourgene Health is planning to sell at least £10.0 million in newly issued shares to institutional investors.